Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury

被引:315
作者
Yang, ZY
Duckers, HJ
Sullivan, NJ
Sanchez, A
Nabel, EG
Nabel, GJ
机构
[1] NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA
[2] NHLBI, Vasc Biol Branch, NIH, Bethesda, MD 20892 USA
[3] Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
关键词
D O I
10.1038/78654
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Here we defined the main viral determinant of Ebola virus pathogenicity; synthesis of the virion glycoprotein (CP) of Ebola virus Zaire induced cytotoxic effects in human endothelial cells in vitro and in vivo. This effect mapped to a serine-threonine-rich, mucin-like domain of this type I transmembrane glycoprotein, one of seven gene products of the virus. Gene transfer of GP into explanted human or porcine blood vessels caused massive endothelial cell loss within 48 hours that led to a substantial increase in vascular permeability. Deletion of the mucin-like region of GP abolished these effects without affecting protein expression or function. CP derived from the Reston strain of virus, which causes disease in nonhuman primates but not in man, did not disrupt the vasculature of human blood vessels. In contrast, the Zaire CP induced endothelial cell disruption and cytotoxicity in both nonhuman primate and human blood vessels, and the mucin domain was required for this effect. These findings indicate that CP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection.
引用
收藏
页码:886 / 889
页数:4
相关论文
共 19 条
  • [1] Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
    Baize, S
    Leroy, EM
    Georges-Courbot, MC
    Capron, M
    Lansoud-Soukate, J
    Debré, P
    Fisher-Hoch, SP
    McCormick, JB
    McCormick, JB
    Georges, AJ
    [J]. NATURE MEDICINE, 1999, 5 (04) : 423 - 426
  • [2] PATHOLOGY OF EXPERIMENTAL EBOLA VIRUS-INFECTION IN MONKEYS
    BASKERVILLE, A
    BOWEN, ETW
    PLATT, GS
    MCARDELL, LB
    SIMPSON, DIH
    [J]. JOURNAL OF PATHOLOGY, 1978, 125 (03) : 131 - &
  • [3] ULTRASTRUCTURAL PATHOLOGY OF EXPERIMENTAL EBOLA HEMORRHAGIC-FEVER VIRUS-INFECTION
    BASKERVILLE, A
    FISHERHOCH, SP
    NEILD, GH
    DOWSETT, AB
    [J]. JOURNAL OF PATHOLOGY, 1985, 147 (03) : 199 - 209
  • [4] BOWEN ETW, 1977, LANCET, V1, P571
  • [5] CDC, 1995, MMWR-MORBID MORTAL W, V44, P381
  • [6] CHARACTERIZATION OF FILOVIRUSES BASED ON DIFFERENCES IN STRUCTURE AND ANTIGENICITY OF THE VIRION GLYCOPROTEIN
    FELDMANN, H
    NICHOL, ST
    KLENK, HD
    PETERS, CJ
    SANCHEZ, A
    [J]. VIROLOGY, 1994, 199 (02) : 469 - 473
  • [7] Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages
    Feldmann, H
    Bugany, H
    Mahner, F
    Klenk, HD
    Drenckhahn, D
    Schnittler, HJ
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (04) : 2208 - 2214
  • [8] Mbiene JP, 1997, J COMP NEUROL, V377, P324, DOI 10.1002/(SICI)1096-9861(19970120)377:3<324::AID-CNE2>3.0.CO
  • [9] 2-4
  • [10] GENE-THERAPY FOR VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION AFTER ARTERIAL INJURY
    OHNO, T
    GORDON, D
    SAN, H
    POMPILI, VJ
    IMPERIALE, MJ
    NABEL, GJ
    NABEL, EG
    [J]. SCIENCE, 1994, 265 (5173) : 781 - 784